Wexford Capital LP Purchases 34,243 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Wexford Capital LP increased its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 15.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 252,122 shares of the company’s stock after acquiring an additional 34,243 shares during the quarter. Wexford Capital LP owned about 0.16% of Neumora Therapeutics worth $2,672,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $64,000. Quantbot Technologies LP purchased a new stake in Neumora Therapeutics during the 4th quarter worth approximately $92,000. PEAK6 LLC purchased a new stake in Neumora Therapeutics during the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC purchased a new stake in Neumora Therapeutics during the 4th quarter worth approximately $135,000. Institutional investors own 47.65% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Stifel Nicolaus downgraded shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. William Blair downgraded shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Bank of America reissued an “underperform” rating and set a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Neumora Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.29.

Neumora Therapeutics Price Performance

NMRA stock opened at $0.70 on Monday. The firm’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $4.24. The company has a market capitalization of $113.22 million, a P/E ratio of -0.37 and a beta of 2.96. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). As a group, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.